3rd Annual Chair Summit - Master Class for Neuroscience Professional Development
neuroscienceCME Medical Meeting
Symposium Dates: August 26-29, 2010Location: Marriott Downtown Magnificent Mile
540 North Michigan Avenue, Chicago, IL 60611
800.228.9290 (rooms reserved under CME Outfitters)
Registration Fees: (click here for more information)
- Early bird registration: $299
(available for one month after registration opens) - Standard registration: $349
(until capacity is reached; call for space availability) - Group registration: up to $25 off
Groups of 2 to 4: $10 off each registration
Groups of 5 or more: $25 off each registration
- Previous Chair Summit participants: $249
- Military personnel, medical students, and residents:
50% off the current rate (proof of status required)
No other discount offer may be used in conjunction with the military/student/resident discount.
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
 | David A. Baron, MSEd, DO Professor, Department of Psychiatry Keck School of Medicine University of Southern California Chief of Psychiatry, University Hospital Director, Global Center for Exercise, Psychiatry and Sport at USC Vice Chair, Department of Psychiatry Los Angeles, CA |
 | Ryan Finkenbine, MD Professor and Chair Department of Psychiatry and Behavioral Medicine University of Illinois College of Medicine at Peoria Peoria, IL |
 | Mark S. Gold, MD Donald R. Dizney Eminent Scholar and Distinguished Professor University of Florida College of Medicine & McKnight Brain Institute Departments of Psychiatry, Neuroscience, Anesthesiology, Community Health & Family Medicine Chairman of the Department of Psychiatry Gainesville, FL |
 | Wayne K. Goodman, MD Professor and Chair Department of Psychiatry Mount Sinai School of Medicine New York, NY |
 | James A. Greene, MD Professor and Chairman Department of Psychiatry University of Tennessee Health Science Center Memphis, TN |
 | Robert M. A. Hirschfeld, MD Titus H. Harris Chair Harry K. Davis Professor Professor and Chairperson Department of Psychiatry University of Texas Medical Branch Galveston, TX |
 | Ned H. Kalin, MD Hedberg Professor and Chair, Department of Psychiatry Director, HealthEmotions Research Institute University of Wisconsin - Madison Madison, WI |
 | Anand Kumar, MD Professor and Head Department of Psychiatry, College of Medicine University of Illinois at Chicago Chicago, IL |
 | Jeffrey A. Lieberman, MD Chairman, Department of Psychiatry College of Physicians and Surgeons, Columbia, Columbia University Director, New York State Psychiatric Institute Director, Lieber Center for Schizophrenia Research Psychiatrist-in-Chief at New York Presbyterian Hospital and Columbia University Medical Center New York, NY |
 | W. Vaughn McCall, MD, MS Professor and Chair Department of Psychiatry and Behavioral Medicine Wake Forest University Health Sciences Winston-Salem, NC |
 | Meera Narasimhan, MD Professor and Interim Chairman Department of Neuropsychiatry and Behavioral Science University of South Carolina School of Medicine Charleston, SC |
 | Charles B. Nemeroff, MD, PhD Professor and Chairman Department of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL |
 | Michael Racke, MD Professor and Chairman in Neurology The Helen C. Kurthz Chair in Neurology Department of Neurology Ohio State University Medical Center Columbus, OH |
 | Mark H. Rapaport, MD Chairman and Professor Department of Psychiatry and Behavioral Neurosciences Cedars-Sinai Medical Center The Polier Endowed Chair in Schizophrenia and Related Disorders Vice Chairman and Professor in Residence Department of Psychiatry and Biobehavioral Sciences David Geffen School of Medicine at UCLA Los Angeles, CA |
 | Alan F. Schatzberg, MD Kenneth T. Norris, Jr. Professor and Chairman Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine Stanford, CA |
 | Russell E. Scheffer, MD Chair and Professor Department of Psychiatry and Behavioral Sciences University of Kansas School of Medicine-Wichita Wichita, KS |
 | S. Charles Schulz, MD Professor & Head Donald W. Hastings Endowed Chair Department of Psychiatry University of Minnesota Medical School Minneapolis, MN |
 | Stephen M. Strakowski, MD The Dr. Stanley & Mickey Kaplan Professor and Chairman of Psychiatry and Behavioral Neuroscience Director, UCCOM Center for Imaging Research Director, Brain Imaging Center at the Lindner Center of HOPE Professor of Psychology and Biomedical Engineering Cincinnati, OH |
 | Thaddeus P. M. Ulzen, MD, FRCP(C), FAPA Professor and Chair Department of Psychiatry and Behavioral Medicine University Medical Center/College of Community Health Sciences Associate Dean for Academic Affairs University of Alabama School of Medicine (Tuscaloosa Campus) Tuscaloosa, AL |
 | Daniel R. Weinberger, MD Professor of Psychiatry George Washington University Washington, DC |
 | Daniel K. Winstead, MD Robert G. Heath Professor and Chairman Department of Psychiatry and Behavioral Sciences Tulane University School of Medicine New Orleans, LA |
Co-provided by
To collaboratively evaluate evidence, share ideas and challenges with peers, and develop individualized strategies that will result in improved patient outcomes.
At the end of this CE activity, participants should be able to:
- Analyze the latest research and clinical data regarding various psychiatric disorders.
- Evaluate the application of evidence-based data in your clinical practice.
- Translate evidence into improved clinical performance to improve outcomes of patients.
This continuing education activity is co-sponsored by USF Health and CME Outfitters, LLC, and supported by educational grants from various organizations. Disclosures of financial supporters will be added to this page as they become available.
USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from AstraZeneca Pharmaceuticals in support of this CE activity.
This activity is supported by an independent educational grant from Cephalon, Inc.
This program is supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Supported by an educational grant from Pfizer Inc.
This educational activity is supported by an independent educational grant from Sepracor Inc.
Physicians, physician assistants, nurse practitioners, nurses, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
USF Health designates this educational activity for a maximum of 22.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 22 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 22.00 continuing education contact hours.
CCMC Credit (Certified Case Managers):
This program has been approved for 22 hours by the Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 22.0 contact hours (2.2 CEUs)
Universal Program Number: 376-999-10-015-L04-P
Activity Type: knowledge-based
Online evaluation and certification will be available.
Disclosure Declaration
CME Outfitters, LLC, reserves the right to update the list of faculty or make necessary changes in names, titles, affiliations, and other details without notice.
USF Health adheres to the ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made in the course syllabus.
Dr. Baron has no disclosures to report.
Dr. Finkenbine has disclosed that he serves on the speaker’s bureau of Eli Lilly and Company.
Dr. Gold has no disclosures to report.
Dr. Goodman has disclosed that he has served as a consultant (DBS trainer) for Medtronic, Inc.
Dr. Greene has disclosed that he is a shareholder of Psychiatric Medical Care, LLC.
Dr. Hirschfeld has disclosed that he serves on the advisory board of and is a consultant to Equinox Group. He receives royalties from Taylor and Francis Group, Jones and Bartlett Publishers.
Dr. Kalin has disclosed that he serves on the advisory boards of AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CeNeRx BioPharma, CME Outfitters, LLC, Corcept Therapeutics, Eli Lilly and Company, Elsevier, Letters & Sciences, Medivation, Inc., Otsuka American Pharmaceuticals, Sanofi-Aventis, and Wyeth Pharmaceuticals. He is a stockholder of/has equity options in Corcept Therapeutics and CeNeRx BioPharma. Dr. Kalin is the owner of Promoter Neurosciences, LLC, and holds patents for the following: promoter sequences for corticotropin-releasing factor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences (U.S. Patent issued on 07-04-06; patent #7071323, U.S. Patent issued on 05-12-09; patent #7,531,356); promoter sequences for urocortin II and the use thereof (U.S. Patent issued on 08-08-06; patent #7087385); and promoter sequences for corticotropin-releasing factor binding protein and use thereof (U.S. Patent issued on 10-17-06; patent #7122650).
Dr. Kumar has disclosed that he receives grants/research support from the National Institutes of Health and the National Institute of Mental Health. He receives a salary for contractual services as Associate Editor of the American Journal of Geriatric Psychiatry.
Dr. Lieberman has disclosed that he serves on the advisory boards of Bioline, GlaxoSmithKline, Intra-Cellular Therapies, Inc., Eli Lilly and Company, Pierre Fabre Laboratories, PsychoGenics, Inc., and Wyeth Pharmaceuticals. He receives grants/research support from Allon Therapeutics, Forest Laboratories, Inc.,
Merck & Co., Inc., Pfizer Inc., and Sepracor Inc., and he holds a patent from Repligen Corporation. Dr. Lieberman receives no direct financial compensation or salary support for participation in these research, consulting, or advisory board activities.
Dr. McCall has disclosed that he receives research grants from Cephalon, Inc., Sealy Corporation, and Sepracor Inc. He serves on the advisory boards of Merck & Co., Inc, and Sealy Corporation. Dr. McCall receives a salary for contractual services from Sealy Corporation and is on the speakers bureaus of Merck & Co., Inc., and Sepracor Inc.
Dr. Narasimhan has disclosed that she receives grants from Bristol-Myers Squibb Company, Forest Laboratories, Inc., Janssen, L.P., National Institute of Health, and Otsuka America Pharmaceutical, Inc. She has served on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, and Eli Lilly and Company.
Dr. Nemeroff has disclosed that he serves on the scientific advisory boards of CeNeRx BioPharma, NovaDel Pharma, Inc., PharmaNeuroBoost, American Foundation for Suicide Prevention (AFSP), and National Alliance for Research on Schizophrenia and Depression. He serves on the board of directors of American Foundation for Suicide Prevention, Mt. Cook Pharma, Inc., and NovaDel Pharma, Inc. He is a stockholder of/has stock options in CeNeRx BioPharma and NovaDel Pharma, Inc. He owns equity in CeNeRx BioPharma, PharmaNeuroBoost, Revaax Pharma, and Corcept Therapeutics. His other financial Interests include AstraZeneca Pharmaceuticals LP, CeNeRx BioPharma, and PharmaNeuroBoost. Dr. Nemeroff holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Racke has disclosed that he serves as a consultant to Eli Lilly and Company. He receives grants from the National Institute of Mental Health and the National Multiple Sclerosis Society. Dr. Racke receives honoraria for serving on the editorial boards of Archives of Neurology and The Neurologist.
Dr. Rapaport has disclosed that he serves on the advisory boards of Astellas Pharma Inc., Brain Cells, Inc., the National Institute of Mental Health, and Pfizer Inc. He serves as a consultant to Affectis Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Methylation Sciences, Inc., and PAX Pharmaceuticals. Dr. Rapaport receives grants/research support from the National Center for Complementary and Alternative Medicine and the National Institute of Mental Health, and he serves on the data and safety monitoring board of Quintiles Transnational Corp. (for an AstraZeneca Pharmaceuticals LP Protocol).
Dr. Schatzberg has disclosed that he serves as a consultant to BrainCells Inc., CeNeRx BioPharma, Corcept Therapeutics, CNS Response, Inc., Eli Lilly and Company, GlaxoSmithKline, Neuronetics Inc., PharmaNeuroBoost, Sanofi-aventis, and Takeda Pharmaceuticals North America, Inc. He own equity in Amnestix, Inc., BrainCells Inc., CeNeRx BioPharma, Corcept Therapeutics, Forest Laboratories, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Pfizer Inc., PharmaNeuroBoost, Somaxon, and Synosis. Dr. Schatzberg is named inventor on pharmacogenetic use patents on prediction of antidepressant response and use of glucocorticoid antagonists.
Dr. Scheffer has disclosed that he has received research support from Wyeth Pharmaceuticals and that he currently receives research support from the National Institute of Child Health and Human Development.
Dr. Schulz has disclosed that he serves on the advisory boards Biovail Pharmaceuticals, Inc., and Eli Lilly and Company. He receives grants and research support from AstraZeneca Pharmaceuticals LP and Eli Lilly and Company.
Dr. Strakowski has disclosed that he receives research support (grants to the UC Academic Health Center) from AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Janssen, L.P., Martek Biosciences, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, National Alliance for Research on Schizophrenia and Depression, Nutrition 21, Repligen Corporation, and the Thrasher Foundation. He serves as a consultant to Pfizer Inc. (paid directly or through Kendle) and receives speaking honoraria from Adamed, the American Association of Child and Adolescent Psychiatry, and CME Outfitters. He has chaired symposium for Consensus Medical Communications (CME through University of Minnesota; unrestricted grant from Ortho-McNeil, Inc./Janssen, L.P.).
Dr. Ulzen has no disclosures to report.
Dr. Weinberger has no disclosures to report.
Dr. Winstead has disclosed that he receives a salary for contractual services from Tulane University School of Medicine and Tulane University Medical Group.
Discussion of Off-Label Use: Because this course is meant to educate physicians with what is currently in use and what may be available in the future, there may be “off-label” use discussed in the presentations. Speakers have been requested to inform the audience when off-label use is being discussed.
Accommodations for Disabilities: Please notify Jamie Conte at jconte@cmeoutfitters.com or call 877.263.7767 a minimum of 10 working
days in advance of the event if a reasonable accommodation for a disability is needed.
The events, activities, and facilities of this conference are available without regard to race, color, sex, national origin, disability, age, or Vietnam veteran status as provided by law in accordance with USF Health’s and CME Outfitters’ respect for personal dignity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MM-027-082610-90
